Neurology News

A single psychedelic experience increased a range of non-physicalist beliefs, such as consciousness, meaning and purpose, researchers reported in the Journal of Psychopharmacology.

Despite the number of new medications produced to treat a range of neurologic diseases, limited utilization is driven by relatively high cost and similar efficacy to less expensive drugs, according to a study published in Neurology.

Women who underwent assisted reproduction had a similar risk for developing multiple sclerosis as women who conceived without being exposed to assisted reproductive technology, according to a Danish register-based cohort study.

Treatment with nusinersen led to continued and improved motor function up to 5 years after initial dose in infants with spinal muscular atrophy, according to a poster presented at the International Scientific Congress on Spinal Muscular Atrophy.

The manufacturer of Leqembi announced it has submitted a supplemental Biologics License Application to the FDA to support the conversion of its recent accelerated approval to a traditional approval.

Endovascular access to the sensorimotor cortex was shown to be a successful alternative for placing a brain-computer interface in or on the dura compared with open-brain surgery, researchers reported in JAMA Neurology.

Quanterix Corp. announced the validation of a laboratory developed test to quantitatively measure neurofilament light chain in serum as an aid in the evaluation of those who may have neurodegenerative conditions.

Amyloid positron emission tomography scan changes were similar between individuals with autosomal dominant Alzheimer’s disease and those with Down syndrome, researchers reported in The Lancet Neurology.

The FDA has granted accelerated approval for Leqembi for the treatment of Alzheimer’s disease, making it the second approved Alzheimer’s treatment, the agency announced in a press release.

The FDA has given priority review to a biologic license application from UCB for rozanolixizumab, a treatment for adults with generalized myasthenia gravis, the biopharmaceutical company announced in a press release.